Federation des caisses Desjardins du Quebec’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-900	Closed	-$246	–	2574
2022 Q3	$246	Hold	900	–	–	﹤0.01%	2437
2022 Q2	$315	Hold	900	–	–	﹤0.01%	2468
2022 Q1	$612	Hold	900	–	–	﹤0.01%	2468
2021 Q4	$2.08K	Hold	900	–	–	﹤0.01%	2352
2021 Q3	$4.12K	Hold	900	–	–	﹤0.01%	2297
2021 Q2	$4K	Hold	900	–	–	﹤0.01%	2307
2021 Q1	$6.55K	Buy	+900	New	+$7.41K	﹤0.01%	2117

Federation des caisses Desjardins du Quebec's LOGC Position: Q4 2022 in Review

Federation des caisses Desjardins du Quebec sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2022, closing a stake of 900 shares — an estimated $246 sold.

Federation des caisses Desjardins du Quebec first reported a position in LOGC in Q1 2021 and held it in 7 quarters. The position peaked at $6.55K in Q1 2021. 0 funds tracked by Wall St. Rank hold LOGC as of Q4 2022.

Federation des caisses Desjardins du Quebec reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 900 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $246.
Federation des caisses Desjardins du Quebec first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Federation des caisses Desjardins du Quebec's LogicBio Therapeutics, Inc. Common Stock position peaked at $6.55K in Q1 2021.
0 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q4 2022, filed 15 Aug 2024.